Bone LossNCT04402671
Lateral Ridge Augmentation Using Cross-linked or Non-cross-linked Collagen Membrane
A study testing non-cross-linked porcine skin collagen membrane and glutaraldehyde cross-linked bovine collagen membrane in people with Bone Loss, run by Saint-Joseph University at 1 site in Lebanon.
Trial summary
The objective of the present trial is to test clinically, radiographically and histologically , in a lateral alveolar ridge augmentation model (without simultaneous implant placement) the efficiency in supporting bone formation of a glutaraldehyde cross-linked collagen membrane compared to a non-cross-linked collagen… Read more about this study
- Who is it for?
- Ages 20 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Bone Loss
- What is being tested?
- non-cross-linked porcine skin collagen membrane and glutaraldehyde cross-linked bovine collagen membrane
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4 participants
- Where
- 1 siteLebanon
- Study dates
- 1 Mar 2019to 1 Aug 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy patients, non-smokers or smokers<10 cigarettes/day.
- Age between 20 and 75.
- Full mouth bleeding score (FmBS) <20 %.
- Full mouth plaque score (FmPS) <15%.
- Presence of a residual alveolar ridge with residual bone width < 5 mm and adequate
- bone height in the maxilla and the mandible.
- Tooth extraction performed at least 6 weeks before surgery.
- Presence of enough teeth to support an occlusal stent/radiographic guide.
Who cannot join
- Systematic diseases.
- History of radiotherapy in the head and neck region in the last 5 years.
- Active periodontitis on the remaining teeth.
- Pregnancy.
- Allergy to collagen.
- Intake of medications that may have an effect on bone turnover and mucosal healing (i.e., tetracycline within the last month, steroids within the last 6 months, bisphosphonates or fluorides at bone therapeutic levels, vitamin D and metabolites at therapeutic levels within the last 6 months).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Lateral Ridge Augmentation Using Cross-linked or Non-cross-linked Collagen Membrane: a Pilot Randomized Clinical Trial
The objective of the present trial is to test clinically, radiographically and histologically , in a lateral alveolar ridge augmentation model (without simultaneous implant placement) the efficiency in supporting bone formation of a glutaraldehyde cross-linked collagen membrane compared to a non-cross-linked collagen membrane with the use of a composite autograft-xenograft mix prepared in a 1:3 ratio
Read the detailed description
This study is a pilot one, no sample size calculation has been performed. Random allocation was done by the sequentially sealed envelope method.
Interventions
Pre-operative preparation:
- Scaling and root planning and delivering proper hygiene instructions.
- Fabrication of the occlusal stent/radiographic guide (Silicone impression of the concerned arch and pouring of the model. Denture teeth are added on the edentulous space of the cast. A 2 mm thickness clear resin sheet is adapted to the cast with a vacuum forming machine. The borders of the stent are trimmed with a tungsten carbide bur to remove the parts that are covering the soft tissues. At the level of the surgical site, the intaglio of the guide is reduced in a way to prevent any interference with the swollen soft tissues during the one-week CBCT assessment. In the middle of each denture tooth, 2 mm cylindrical holes are created occlusally. Gutta-percha is inserted in these holes to serve as radio-opaque markers and as reference points for per-operative measurements.
- Pre-operative Cone Beam CT (CBCTpreop) with the radiographic guide/occlusal stent in the mouth
Surgical intervention:
Patients are put on an antibiotic regimen consisting of 1 g co-amoxiclav taken twice daily (Augmentin, GlaxoSmithKline, Brentford, United Kingdom), starting the evening prior to surgery and continued for 10 days. For patients allergic to penicillins, Clindamycin 300 mg taken every 6 hours (Dalacin C, Pfeizer, New York City, NY, USA) is prescribed. Before surgery, the patient is asked to rinse with 0.12% chlorhexidine solution for one minute. Local anesthesia is delivered using 4% articaine with epinephrine 1:100,000 (Septanest, Septodont, Saint Maur des Fosses, France). After mid-crestal and vertical releasing incisions are being made, full thickness flaps are raised. The recipient bone is curetted to remove any soft tissue that may impede bone healing. Using a ridge mapping caliper, Crestal Bone Width is recorded at 1 (CBWpreop1), 3 (CBWpreop3) and 5 (CBWpreop5) mm from the crest at the level of the gutta-percha markers of the guide. Using a periodontal probe, another measure is recorded from the Ridge Crest to the Border of the Guide (RC-BG). This measure will be used at the 6-month re-entry to locate the vertical position of the pre-operative ridge mapping measurements in case of vertical bone changes. On the buccal flaps, superficial periosteal releasing incisions are performed to release the flap tension and to access the submucosal tissues. Once accessed, the submucosal tissues are stretched by inserting the wide end of a periosteal elevator into the incision line and pushing it in a coronal direction, resulting in flap elongation. In the posterior mandible, the lingual flap is elongated by a lateral stretching movement using the wide end of the periosteal elevator to separate the sub-mucosal tissues from the underlying muscle. More anteriorly in the mandible, a superficial periosteal incision is performed in the lingual flap. The buccal aspect of the crest is decorticated to ensure vascularization at the recipient site. The particulate bone graft consisting of a composite autograft-xenograft is then prepared in a 1:3 ratio mixed in sterile saline. A 0.5 cc spoon is used to have an exact 1:3 ratio. The spoon is slightly overfilled, and the excess is eliminated with a spatula. Only the full spoon content is used in the bone graft mix. The autograft is obtained by scraping the adjacent bony region with a bone scraper (SafeScraper TWIST, META, Reggio Emilia, Italy). The xenograft used is an anorganic bovine bone mineral with a 250-1000 microns particle size (OCS-B Xenomatrix®, Nibec, Chungcheongbuk-do, Korea, available also under the name of Straumann Xenograft® and Creos Xenogain®). After opening the sequentially sealed envelope, the patient is allocated to test or control groups. In the test group a glutaraldehyde cross-linked bovine collagen membrane GCLM is used (RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA), in the control group a non-cross-linked porcine skin collagen membrane is used (Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland). The membrane is fixed first on the buccal side with titanium pins (Masetrpin®, Meisinger, Neuss, Germany) in a way to create a pouch like space. Second, the composite graft is applied between the membrane and the crest with a slight over fill. Then the membrane is slightly stretched, wrapped over the ridge and tightly stabilized palatally/lingually with titanium pins. The graft-membrane complex should be completely immobile at finger pressure. A tight wound closure is achieved by placing a first line of horizontal mattress sutures followed by a second line of interrupted sutures along the horizontal incision. The vertical releasing incisions are closed with a combination of Laurel-Gottlow sutures and interrupted sutures. The sutures used are 4(0) PTFE monofilament sutures (Osteogenics Biomedical, Lubbock, TX, USA). Beside the antibiotic regimen described earlier, all patients are prescribed 0.12% chlorhexidine mouthwash (twice daily for 2 weeks, starting from the day after surgery), NSAIDs drugs (Bruffen 400mg every 6 hours, Abbott Laboratories, Illinois, CHI, USA) and/or paracetamol-opioid analgesics (Solpadeine, Omega Pharma Nazareth, Belgium). An extraoral cold pressure dressing is applied to minimize postoperative swelling. Sutures are removed 3 weeks after surgery.
During the first week after surgery, a Cone Beam CT (CBCTpostop) of the operated region is performed, with the radiographic guide in place.
Follow-up visits will be performed after 1, 3, 6, 10, 14, 18, 22 and 26 weeks.
Re-entry:
At 6 months post-surgery, another Cone Beam CT (CBCTre), with the same radiographic guide in place, is taken for bone volume assessment and for implant planning. Mid-crestal and vertical releasing incisions are made. Full thickness flaps are raised, and the pins are removed. Any non-integrated bone graft material is gently scraped and washed out with saline. The guide is put in place and using the previously recorded RC-BG measurement to correctly locate the level of the ridge crest before the ridge augmentation surgery, Crestal Bone Width is recorded with the ridge mapping caliper at the same locations (CBWre1, CBWre3, CBWre5) taken during the regeneration surgery. In addition, a UNC-15 periodontal probe is pushed with pressure against the ridge at a 45 degrees angle at the level of each gutta-percha marker and at 3 mm form the ridge top. The amount probe penetration in the grafted bone volume is recorded.
A 2 mm diameter trephine bone biopsy is collected for histomorphometrical and immunohistochemichal analysis. When possible, the biopsy is extracted horizontally from the buccal aspect of the ridge at 4 mm from the crest, otherwise it will be collected vertically from the ridge top. One biopsy is collected per patient, taken where the lateral ridge defect is the most severe.
Then the implants are inserted, at the prosthetically planned positions, according to the manufacturer's instructions. Flaps are sutured and a post-operative medication is prescribed consisting of an antibiotic coverage, an analgesic, and a chlorhexidine mouthwash.
Three months later, the implants are uncovered for abutment connection and will be subsequently restored.
- Conditions
- Bone Loss
- Being tested
- non-cross-linked porcine skin collagen membrane, glutaraldehyde cross-linked bovine collagen membrane
- Keywords
- Guided bone regeneration, collagen membrane, crosslinked collagen membrane, Bone augmentation
- Medical subject headings
- Bone Diseases, Metabolic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
non-cross-linked porcine skin collagen membraneOther
Also called Bioguide
non-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland.
glutaraldehyde cross-linked bovine collagen membraneOther
Also called Cytoplast RTM
glutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA.
| Study group | Role | What they receive |
|---|---|---|
| non-crosslinked collagen membrane group | Active comparator | 2 patients (1 male, 1 female) Receives: Other: non-cross-linked porcine skin collagen membrane |
| glutaraldehyde cross-linked collagen membrane | Active comparator | 2 patients (2 females) Receives: Other: glutaraldehyde cross-linked bovine collagen membrane |
What is being measured
The primary outcome is the main question the study is designed to answer.
Linear measurements outcomes
the ridge mapping changes in linear measurements between initial ridge width and reentry ridge width at 1, 3 and 5 mm from the ridge crest
Measured: 6 - 9 months
Secondary outcomes (9)
Volumetric measurements outcome
Pre-operative Cone Beam CT (CBCTpreop), a Cone Beam CT the first week after surgery (CBCTpostop), and a Cone Beam CT at re-entry post-surgery (CBCTre), with the radiographic guide/occlusal stent in the mouth, are taken.
DICOM files from the 3 CBCT scans are uploaded to the BlueSky Plan software (BlueSkyBio, Grayslake, IL, USA) and are superimposed using the gutta-percha markers of the radiographic guide. The Region Of Interest (ROI) is delineated Vpreop, Vpostop and Vre are the volume in cubic millimeters of the ROI measured from the CBCTpreop, CBCTpostop and the CBCTre, respectively.
The volumetric outcomes from the DICOM data are used for each group to calculate:
- the volume of graft resorption.
- the graft volume created after GBR
- the bone volume gain.
Measured: 6 - 9 months
the percentage of graft volume resorption.
The percentage of graft volume resorption is calculated by deviding the volume of the graft resorbtion on the volume created after GBR
Measured: 6 - 9 months
Linear measurements outcomes on DICOM data
On each gutta percha site on the DICOM files these measurements are assessed:
Linear measurements in millimeters at 1, 3, 5 mm from the ridge crest in a plane orthogonally bisecting the dental arch at the level of each gutta-percha marker, taken form the ROI of CBCTpreop and CBCTre respectively.
The changes of the linear measurements outcomes on DICOM data between CBCTpreop and CBCTre.
Measured: 6 - 9 months
Soft tissue healing
Soft tissue healing will be assessed during the follow-up visits for the following occurrences Redness and swelling. Wound dehiscence and membrane exposure. Infections or any other unaccounted complications will be recorded
Measured: 6 - 9 months
Periodontal Probe Penetration (PP)
PP reflecting the amount of graft maturation is recorded and compared between sites and between patients.
Measured: 6 - 9 months
Histology
Histology analysis of the bone biopsies taken from the regenerated crests at re-entry surgery
Measured: 6 - 9 months
Histomorphometry: percentage of new bone formation
Calculation of Percentage new bone formation in the bone biopsies taken from the regenerated crests at re-entry
Measured: 6 - 9 months
Histomorphometry: percentage of remaining graft particles
Calculation of the percentage remaining graft particles in the bone biopsies taken from the regenerated crests at re-entry
Measured: 6 - 9 months
Histomorphometry: percentage of connective tissue
Calculation of the percentage of connective tissue in the bone biopsies taken from the regenerated crests at re-entry
Measured: 6 - 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2020
- Study start1 Mar 2019
- Primary completion1 Aug 2020
- Study completion1 Aug 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bone LossStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a pilot randomized clinical trial with parallel groups, with an observation period of 6 - 9 months. It is set to identify the equivalence between the test and the control procedures. An equal randomization is set for the 2 groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 4 participants (actual)
Sponsor and investigators
- Lead sponsor
- Saint-Joseph University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mario Haddad, Saint-Joseph University
- Investigators
- Carole F Chakar, PhD, Study director, Saint-Joseph University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04402671
- Sponsor's protocol ID
- FMD188
- Status last verified
- Oct 2020
- First submitted
- 15 May 2020
- Last updated
- 22 Oct 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD that underlie results in a publication
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lateral Ridge Augmentation Using Cross-linked or Non-cross-linked Collagen Membrane: a Pilot Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT04402671
- Acronym / sponsor ID
- FMD188
- Conditions
- Bone Loss
- Keywords
- Guided bone regeneration, collagen membrane, crosslinked collagen membrane, Bone augmentation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 4 participants (actual)
- Lead sponsor
- Saint-Joseph UniversityUniversity, hospital or other
- Study start
- 1 Mar 2019 (actual)
- Primary completion
- 1 Aug 2020 (actual)
- Study completion
- 1 Aug 2020 (actual)
- First posted
- 27 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the present trial is to test clinically, radiographically and histologically , in a lateral alveolar ridge augmentation model (without simultaneous implant placement) the efficiency in supporting bone formation of a glutaraldehyde cross-linked collagen membrane compared to a non-cross-linked collagen membrane with the use of a composite autograft-xenograft mix prepared in a 1:3 ratio
Detailed description
This study is a pilot one, no sample size calculation has been performed. Random allocation was done by the sequentially sealed envelope method.
Interventions
Pre-operative preparation:
- Scaling and root planning and delivering proper hygiene instructions.
- Fabrication of the occlusal stent/radiographic guide (Silicone impression of the concerned arch and pouring of the model. Denture teeth are added on the edentulous space of the cast. A 2 mm thickness clear resin sheet is adapted to the cast with a vacuum forming machine. The borders of the stent are trimmed with a tungsten carbide bur to remove the parts that are covering the soft tissues. At the level of the surgical site, the intaglio of the guide is reduced in a way to prevent any interference with the swollen soft tissues during the one-week CBCT assessment. In the middle of each denture tooth, 2 mm cylindrical holes are created occlusally. Gutta-percha is inserted in these holes to serve as radio-opaque markers and as reference points for per-operative measurements.
- Pre-operative Cone Beam CT (CBCTpreop) with the radiographic guide/occlusal stent in the mouth
Surgical intervention:
Patients are put on an antibiotic regimen consisting of 1 g co-amoxiclav taken twice daily (Augmentin, GlaxoSmithKline, Brentford, United Kingdom), starting the evening prior to surgery and continued for 10 days. For patients allergic to penicillins, Clindamycin 300 mg taken every 6 hours (Dalacin C, Pfeizer, New York City, NY, USA) is prescribed. Before surgery, the patient is asked to rinse with 0.12% chlorhexidine solution for one minute. Local anesthesia is delivered using 4% articaine with epinephrine 1:100,000 (Septanest, Septodont, Saint Maur des Fosses, France). After mid-crestal and vertical releasing incisions are being made, full thickness flaps are raised. The recipient bone is curetted to remove any soft tissue that may impede bone healing. Using a ridge mapping caliper, Crestal Bone Width is recorded at 1 (CBWpreop1), 3 (CBWpreop3) and 5 (CBWpreop5) mm from the crest at the level of the gutta-percha markers of the guide. Using a periodontal probe, another measure is recorded from the Ridge Crest to the Border of the Guide (RC-BG). This measure will be used at the 6-month re-entry to locate the vertical position of the pre-operative ridge mapping measurements in case of vertical bone changes. On the buccal flaps, superficial periosteal releasing incisions are performed to release the flap tension and to access the submucosal tissues. Once accessed, the submucosal tissues are stretched by inserting the wide end of a periosteal elevator into the incision line and pushing it in a coronal direction, resulting in flap elongation. In the posterior mandible, the lingual flap is elongated by a lateral stretching movement using the wide end of the periosteal elevator to separate the sub-mucosal tissues from the underlying muscle. More anteriorly in the mandible, a superficial periosteal incision is performed in the lingual flap. The buccal aspect of the crest is decorticated to ensure vascularization at the recipient site. The particulate bone graft consisting of a composite autograft-xenograft is then prepared in a 1:3 ratio mixed in sterile saline. A 0.5 cc spoon is used to have an exact 1:3 ratio. The spoon is slightly overfilled, and the excess is eliminated with a spatula. Only the full spoon content is used in the bone graft mix. The autograft is obtained by scraping the adjacent bony region with a bone scraper (SafeScraper TWIST, META, Reggio Emilia, Italy). The xenograft used is an anorganic bovine bone mineral with a 250-1000 microns particle size (OCS-B Xenomatrix®, Nibec, Chungcheongbuk-do, Korea, available also under the name of Straumann Xenograft® and Creos Xenogain®). After opening the sequentially sealed envelope, the patient is allocated to test or control groups. In the test group a glutaraldehyde cross-linked bovine collagen membrane GCLM is used (RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA), in the control group a non-cross-linked porcine skin collagen membrane is used (Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland). The membrane is fixed first on the buccal side with titanium pins (Masetrpin®, Meisinger, Neuss, Germany) in a way to create a pouch like space. Second, the composite graft is applied between the membrane and the crest with a slight over fill. Then the membrane is slightly stretched, wrapped over the ridge and tightly stabilized palatally/lingually with titanium pins. The graft-membrane complex should be completely immobile at finger pressure. A tight wound closure is achieved by placing a first line of horizontal mattress sutures followed by a second line of interrupted sutures along the horizontal incision. The vertical releasing incisions are closed with a combination of Laurel-Gottlow sutures and interrupted sutures. The sutures used are 4(0) PTFE monofilament sutures (Osteogenics Biomedical, Lubbock, TX, USA). Beside the antibiotic regimen described earlier, all patients are prescribed 0.12% chlorhexidine mouthwash (twice daily for 2 weeks, starting from the day after surgery), NSAIDs drugs (Bruffen 400mg every 6 hours, Abbott Laboratories, Illinois, CHI, USA) and/or paracetamol-opioid analgesics (Solpadeine, Omega Pharma Nazareth, Belgium). An extraoral cold pressure dressing is applied to minimize postoperative swelling. Sutures are removed 3 weeks after surgery.
During the first week after surgery, a Cone Beam CT (CBCTpostop) of the operated region is performed, with the radiographic guide in place.
Follow-up visits will be performed after 1, 3, 6, 10, 14, 18, 22 and 26 weeks.
Re-entry:
At 6 months post-surgery, another Cone Beam CT (CBCTre), with the same radiographic guide in place, is taken for bone volume assessment and for implant planning. Mid-crestal and vertical releasing incisions are made. Full thickness flaps are raised, and the pins are removed. Any non-integrated bone graft material is gently scraped and washed out with saline. The guide is put in place and using the previously recorded RC-BG measurement to correctly locate the level of the ridge crest before the ridge augmentation surgery, Crestal Bone Width is recorded with the ridge mapping caliper at the same locations (CBWre1, CBWre3, CBWre5) taken during the regeneration surgery. In addition, a UNC-15 periodontal probe is pushed with pressure against the ridge at a 45 degrees angle at the level of each gutta-percha marker and at 3 mm form the ridge top. The amount probe penetration in the grafted bone volume is recorded.
A 2 mm diameter trephine bone biopsy is collected for histomorphometrical and immunohistochemichal analysis. When possible, the biopsy is extracted horizontally from the buccal aspect of the ridge at 4 mm from the crest, otherwise it will be collected vertically from the ridge top. One biopsy is collected per patient, taken where the lateral ridge defect is the most severe.
Then the implants are inserted, at the prosthetically planned positions, according to the manufacturer's instructions. Flaps are sutured and a post-operative medication is prescribed consisting of an antibiotic coverage, an analgesic, and a chlorhexidine mouthwash.
Three months later, the implants are uncovered for abutment connection and will be subsequently restored.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- This study is a pilot randomized clinical trial with parallel groups, with an observation period of 6 - 9 months. It is set to identify the equivalence between the test and the control procedures. An equal randomization is set for the 2 groups
| Arm | Type | Receives |
|---|---|---|
| non-crosslinked collagen membrane group | Active comparator | Other: non-cross-linked porcine skin collagen membrane2 patients (1 male, 1 female) |
| glutaraldehyde cross-linked collagen membrane | Active comparator | Other: glutaraldehyde cross-linked bovine collagen membrane2 patients (2 females) |
Who may qualify
- Ages
- 20 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Healthy patients, non-smokers or smokers<10 cigarettes/day.
- Age between 20 and 75.
- Full mouth bleeding score (FmBS) <20 %.
- Full mouth plaque score (FmPS) <15%.
- Presence of a residual alveolar ridge with residual bone width < 5 mm and adequate
Key exclusion criteria (6 listed)
- Systematic diseases.
- History of radiotherapy in the head and neck region in the last 5 years.
- Active periodontitis on the remaining teeth.
- Pregnancy.
- Allergy to collagen.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| non-cross-linked porcine skin collagen membraneAlso: Bioguidenon-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland. | Other | non-crosslinked collagen membrane group |
| glutaraldehyde cross-linked bovine collagen membraneAlso: Cytoplast RTMglutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA. | Other | glutaraldehyde cross-linked collagen membrane |
Primary outcome
Linear measurements outcomes
Time frame: 6 - 9 months
the ridge mapping changes in linear measurements between initial ridge width and reentry ridge width at 1, 3 and 5 mm from the ridge crest
9 secondary outcomes
Volumetric measurements outcome
Time frame: 6 - 9 months
the percentage of graft volume resorption.
Time frame: 6 - 9 months
Linear measurements outcomes on DICOM data
Time frame: 6 - 9 months
Soft tissue healing
Time frame: 6 - 9 months
Periodontal Probe Penetration (PP)
Time frame: 6 - 9 months
Histology
Time frame: 6 - 9 months
Histomorphometry: percentage of new bone formation
Time frame: 6 - 9 months
Histomorphometry: percentage of remaining graft particles
Time frame: 6 - 9 months
Histomorphometry: percentage of connective tissue
Time frame: 6 - 9 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2020.
- Individual participant dataSharing planned: Yes. All IPD that underlie results in a publication
Related trials for Bone Loss
Recruiting
Hemocoll, Avitene, or Bone Wax for Cancellous Bone Bleeding After Single-Ray Amputation
Hemostasis, Surgical Blood Loss
Enrolling by invitation
Investigation of the Effect of Horizontal Platelet Rich Fibrin Placed in Tooth Extraction Sockets on Bone Formation
Tooth Loss, Dental Implant Failed
RecruitingPhase 2/3
Lactoferrin Nanohydrogel for Soft And Hard Tissue Healing and Implant Stability in Immediate Implant Placement
Dental Implant, Wound Healing
Not yet recruiting
Exercise and Fall Prevention
Osteopenia, Osteoporosis
RecruitingPhase 1
Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia
Osteopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carole F Chakar, PhD study director
Saint-Joseph University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing non-cross-linked porcine skin collagen membrane and glutaraldehyde cross-linked bovine collagen membrane in people with Bone Loss, run by Saint-Joseph University at 1 site in Lebanon.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Lebanon. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Linear measurements outcomes (time frame: 6 - 9 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2020.